Teva has launched a thinner, 29-gauge pre-filled syringe for its multiple sclerosis (MS) treatment, Copaxone (glatiramer acetate) injection. A survey of 562 MS patients found that the thinner needle was significantly preferred by 77% of patients over the previous 27-guage needle. Additionally, 66% of participants experienced less pain while using the thinner needle and almost half of the participants had a better experience dealing with injection-site reactions.
Copaxone is indicated to reduce the frequency of relapses in relapsing-remitting multiple sclerosis (RRMS).
For more information call (800) 887-8100 or visit www.copaxone.com.